Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2026-04-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司独立董事钱令嘉2025年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for Beijing SL Pharmaceutical Co., Ltd. It is a detailed report by an independent director summarizing their duties, attendance at board and committee meetings, oversight activities, and evaluations related to the company's governance and compliance during the 2025 fiscal year. The content focuses on the director's role, board activities, committee participation, and governance oversight rather than financial results or audit opinions. It does not contain financial statements or earnings data, nor is it an announcement or proxy material. This type of document fits best under Board/Management Information (MANG) as it relates to board member duties and governance reporting by a director.
2026-04-28 Chinese
北京双鹭药业股份有限公司关于董事辞职及补选第九届董事会非独立董事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a company director and the nomination of a new non-independent director to the board. It details the resignation circumstances, the nomination process, and qualifications of the new director candidate. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is MANG with high confidence.
2026-04-28 Chinese
北京双鹭药业股份有限公司董事会审计委员会对会计师事务所履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Audit Committee regarding the supervision of the accounting firm (大华会计师事务所) for the company's 2025 annual audit. It discusses the appointment, audit procedures, audit findings, and the committee's evaluation of the auditor's performance. The content focuses on the audit process and results related to the annual financial statements and internal controls for the fiscal year ending December 31, 2025. It is not the full annual report itself but a standalone audit-related report. The document length is about 2012 characters, which is relatively short but contains substantive audit information rather than just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR).
2026-04-28 Chinese
上市公司2025年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the year 2025 for Beijing Shuanglu Pharmaceutical Co., Ltd. It includes financial figures such as beginning balances, amounts incurred, interest, repayments, and ending balances for various related parties. The content is specific to related party transactions and fund usage rather than a full financial report or announcement. The document length is 1907 characters, which is relatively short and does not contain comprehensive financial statements or management discussion. It is not an announcement of a report but a specific financial summary related to related party transactions. This type of document typically falls under Regulatory Filings (RNS) as it is a compliance disclosure of related party transactions and fund usage, which does not fit into other more specific categories like Annual Report, Interim Report, or Capital/Financing Update.
2026-04-28 Chinese
2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as "北京双鹭药业股份有限公司2025年年度报告摘要" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2025 Annual Report Summary." It contains detailed financial data for the year 2025, including revenue, net profit, cash flow, R&D projects, product sales, and shareholder information. The document includes comprehensive financial statements and analysis for the full fiscal year 2025. It is not a brief announcement or a certification letter but a substantive financial report covering the company's yearly performance. Therefore, it fits the definition of an Annual Report (10-K).
2026-04-28 Chinese
北京双鹭药业股份有限公司关于2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2025 annual profit distribution plan of Beijing Shuanglu Pharmaceutical Co., Ltd. It includes details about the profit distribution proposal, cash dividends, and related financial figures. The document is relatively short (2014 characters) and is structured as a formal announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it focuses on the dividend distribution plan and related shareholder information. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2026-04-28 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.